Logo image of CHRS

COHERUS ONCOLOGY INC (CHRS) Stock Price, Forecast & Analysis

USA - NASDAQ:CHRS - US19249H1032 - Common Stock

1.689 USD
-0.01 (-0.65%)
Last: 10/31/2025, 11:27:39 AM

CHRS Key Statistics, Chart & Performance

Key Statistics
Market Cap196.31M
Revenue(TTM)142.77M
Net Income(TTM)179.75M
Shares116.23M
Float105.76M
52 Week High2.43
52 Week Low0.66
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.98
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/amc
IPO2014-11-06
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CHRS short term performance overview.The bars show the price performance of CHRS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80

CHRS long term performance overview.The bars show the price performance of CHRS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 -50 100

The current stock price of CHRS is 1.689 USD. In the past month the price increased by 2.41%. In the past year, price increased by 135.13%.

COHERUS ONCOLOGY INC / CHRS Daily stock chart

CHRS Latest News, Press Relases and Analysis

CHRS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.77 388.61B
AMGN AMGEN INC 13.53 158.82B
GILD GILEAD SCIENCES INC 14.8 150.42B
VRTX VERTEX PHARMACEUTICALS INC 24.97 108.46B
REGN REGENERON PHARMACEUTICALS 14.57 69.50B
ALNY ALNYLAM PHARMACEUTICALS INC 343.64 58.56B
ARGX ARGENX SE - ADR 61.69 50.33B
INSM INSMED INC N/A 40.49B
ONC BEONE MEDICINES LTD-ADR 4.99 33.97B
NTRA NATERA INC N/A 27.12B
BNTX BIONTECH SE-ADR N/A 24.85B
BIIB BIOGEN INC 9.14 22.44B

About CHRS

Company Profile

CHRS logo image Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 177 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).

Company Info

COHERUS ONCOLOGY INC

333 Twin Dolphin Dr, Suite 600, 201 Redwood Shores Parkway, Suite 200

Redwood City CALIFORNIA 94065 US

CEO: Dennis M. Lanfear

Employees: 177

CHRS Company Website

CHRS Investor Relations

Phone: 16506493530

COHERUS ONCOLOGY INC / CHRS FAQ

What does COHERUS ONCOLOGY INC do?

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 177 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).


Can you provide the latest stock price for COHERUS ONCOLOGY INC?

The current stock price of CHRS is 1.689 USD. The price decreased by -0.65% in the last trading session.


What is the dividend status of COHERUS ONCOLOGY INC?

CHRS does not pay a dividend.


What is the ChartMill rating of COHERUS ONCOLOGY INC stock?

CHRS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Which stock exchange lists CHRS stock?

CHRS stock is listed on the Nasdaq exchange.


How many employees does COHERUS ONCOLOGY INC have?

COHERUS ONCOLOGY INC (CHRS) currently has 177 employees.


When does COHERUS ONCOLOGY INC (CHRS) report earnings?

COHERUS ONCOLOGY INC (CHRS) will report earnings on 2025-11-10, after the market close.


CHRS Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to CHRS. When comparing the yearly performance of all stocks, CHRS is one of the better performing stocks in the market, outperforming 96.55% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CHRS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CHRS. CHRS has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CHRS Financial Highlights

Over the last trailing twelve months CHRS reported a non-GAAP Earnings per Share(EPS) of -0.98. The EPS increased by 27.41% compared to the year before.


Industry RankSector Rank
PM (TTM) 125.9%
ROA 40.9%
ROE 150.01%
Debt/Equity 0.42
Chartmill High Growth Momentum
EPS Q2Q%-142.86%
Sales Q2Q%-84.22%
EPS 1Y (TTM)27.41%
Revenue 1Y (TTM)-53.67%

CHRS Forecast & Estimates

11 analysts have analysed CHRS and the average price target is 5.78 USD. This implies a price increase of 242.22% is expected in the next year compared to the current price of 1.689.

For the next year, analysts expect an EPS growth of -66.6% and a revenue growth -82.03% for CHRS


Analysts
Analysts81.82
Price Target5.78 (242.21%)
EPS Next Y-66.6%
Revenue Next Year-82.03%

CHRS Ownership

Ownership
Inst Owners44.86%
Ins Owners6.31%
Short Float %28.52%
Short Ratio24.52